CME
Q4 2026 EPS Estimate
$2.96
Oct 28, 2026 · Reports before open
Revenue Estimate
$1.70B
FY2026E EPS$12.25
FY2027E EPS$12.92

Analyst Sentiment

Wall St. Consensus
Hold
22 analysts·High coverage
59
Score
12 Buy (55%)6 Hold (27%)4 Sell (18%)
Rating Breakdown
Strong Buy
00%
Buy
1255%
Hold
627%
Sell
418%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$260.00
-3.6%
Consensus
$316.00
+17.1%
Bull
$330.00
+22.3%
12-Month Target Range22 analysts
$260.00$316.00$330.00
Current $269.80Consensus
Current Price
$269.80
Upside to Consensus
$46.20

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+5.04%
EPS+5.41%
FY2028
Rev+6.48%
EPS+7.34%
FY2029
Rev+7.60%
EPS+8.14%
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029EFY2030E
Revenue Avg$7.03B$7.38B$7.86B$8.46B$8.73B
Low$6.98B$7.03B$7.41B$8.14B$8.40B
High$7.16B$7.59B$8.21B$8.76B$9.04B
EBITDA Avg$6.42B$6.74B$7.18B$7.72B$7.97B
Low$6.37B$6.42B$6.76B$7.43B$7.67B
High$6.53B$6.93B$7.49B$7.99B$8.25B
EBIT Avg$6.31B$6.63B$7.05B$7.59B$7.83B
Low$6.26B$6.31B$6.65B$7.31B$7.54B
High$6.42B$6.81B$7.36B$7.86B$8.11B
Net Income Avg$4.43B$4.62B$4.92B$5.40B$5.78B
Low$4.35B$4.39B$4.76B$5.14B$5.50B
High$4.54B$4.81B$5.14B$5.65B$6.05B
EPS Avg$12.25$12.92$13.86$14.99$16.05
Low$12.07$12.18$13.20$14.26$15.27
High$12.60$13.34$14.27$15.68$16.79
Analysts (Rev / EPS)11 / 1011 / 107 / 43 / 15 / 1
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027Q1 2028Q2 2028
Revenue Avg$1.70B$1.75B$1.85B$1.83B$1.82B$1.89B$2.04B$1.94B
Low$1.69B$1.70B$1.79B$1.77B$1.77B$1.83B$1.97B$1.88B
High$1.72B$1.79B$1.93B$1.91B$1.90B$1.97B$2.13B$2.03B
EBITDA Avg$1.55B$1.59B$1.69B$1.67B$1.66B$1.73B$1.86B$1.77B
Low$1.54B$1.56B$1.63B$1.62B$1.61B$1.67B$1.80B$1.72B
High$1.57B$1.63B$1.76B$1.74B$1.74B$1.80B$1.94B$1.85B
EBIT Avg$1.52B$1.57B$1.66B$1.64B$1.64B$1.70B$1.83B$1.74B
Low$1.51B$1.53B$1.61B$1.59B$1.58B$1.64B$1.77B$1.69B
High$1.54B$1.60B$1.73B$1.71B$1.71B$1.77B$1.91B$1.82B
Net Income Avg$1.07B$1.08B$1.19B$1.17B$1.16B$1.18B$1.36B$1.27B
Low$1.02B$1.05B$1.14B$1.12B$1.12B$1.13B$1.30B$1.22B
High$1.13B$1.11B$1.26B$1.24B$1.23B$1.25B$1.44B$1.34B
EPS Avg$2.94$2.97$3.29$3.23$3.21$3.26$3.75$3.51
Low$2.82$2.89$3.15$3.09$3.08$3.13$3.59$3.36
High$3.13$3.05$3.47$3.41$3.39$3.45$3.96$3.71
Analysts (Rev / EPS)7 / 107 / 103 / 83 / 83 / 86 / 85 / 94 / 9

Earnings Surprises

Recent Analyst Actions

Jul 23, 2026Morgan Stanley
CME Group price target raised to $330 from $324 at Morgan Stanley
Target:$330.00
+30.5%from $252.80
Jul 15, 2026Piper Sandler
CME Group price target lowered to $295 from $329 at Piper Sandler
Target:$295.00
+21.1%from $243.61
Jul 10, 2026Morgan Stanley
CME Group price target lowered to $324 from $353 at Morgan Stanley
Target:$324.00
+36.4%from $237.46
Jul 6, 2026UBS
CME Group price target lowered to $260 from $310 at UBS
Target:$260.00
+9.9%from $236.60
Jun 17, 2026Piper Sandler
Piper Sandler Reiterates CME Group (CME) at Outperform following CEO Duffy's resignation
Target:$320.00
+29.0%from $248.12
Jun 15, 2026Piper Sandler
Piper Sandler Reiterates Overweight Rating on CME Group (CME)
Target:$329.00
+22.8%from $267.85
Jun 11, 2026Redburn Partners
CME Group upgraded to Buy from Neutral at Rothschild & Co Redburn
Target:$323.00
+22.4%from $263.80
Apr 23, 2026Morgan Stanley
CME Group price target lowered to $353 from $362 at Morgan Stanley
Target:$353.00
+25.0%from $282.44
Apr 23, 2026Barclays
CME Group price target lowered to $316 from $343 at Barclays
Target:$316.00
+10.6%from $285.71
Apr 10, 2026Morgan Stanley
CME Group price target raised to $362 from $340 at Morgan Stanley
Target:$362.00
+22.8%from $294.81
Feb 6, 2026UBS
CME Group price target raised to $310 from $280 at UBS
Target:$310.00
+4.2%from $297.38
Feb 5, 2026RBC Capital
CME Group price target raised to $302 from $295 at RBC Capital
Target:$302.00
+0.5%from $300.42
Feb 5, 2026Morgan Stanley
CME Group price target raised to $340 from $319 at Morgan Stanley
Target:$340.00
+15.4%from $294.62
Feb 5, 2026Barclays
CME Group price target raised to $312 from $304 at Barclays
Target:$312.00
+5.9%from $294.62
Jan 15, 2026Morgan Stanley
CME Group price target lowered to $319 from $320 at Morgan Stanley
Target:$319.00
+16.7%from $273.41
Dec 22, 2025Morgan Stanley
CME Group price target raised to $320 from $314 at Morgan Stanley
Target:$320.00
+18.9%from $269.09
Dec 12, 2025Barclays
CME Group price target raised to $304 from $280 at Barclays
Target:$304.00
+11.6%from $272.42
Oct 23, 2025Morgan Stanley
CME Group price target raised to $314 from $312 at Morgan Stanley
Target:$314.00
+16.5%from $269.50
Oct 23, 2025UBS
CME Group price target lowered to $280 from $285 at UBS
Target:$280.00
+4.6%from $267.81
Oct 23, 2025Deutsche Bank
CME Group upgraded to Buy from Hold at Deutsche Bank
Target:$300.00
+11.3%from $269.59
Oct 13, 2025Raymond James
CME Group price target lowered to $307 from $309 at Raymond James
Target:$307.00
+13.1%from $271.45
Oct 8, 2025Barclays
CME Group price target lowered to $280 from $298 at Barclays
Target:$280.00
+6.2%from $263.60
Oct 1, 2025Morgan Stanley
CME Group price target raised to $312 from $303 at Morgan Stanley
Target:$312.00
+18.0%from $264.46
Sep 8, 2025UBS
CME Group price target lowered to $285 from $305 at UBS
Target:$285.00
+8.9%from $261.78
Jul 24, 2025Barclays
CME Group price target lowered to $298 from $299 at Barclays
Target:$298.00
+7.5%from $277.18
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.